Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TGF-β mRNA 3'UTR is a critical regulatory region of the messenger RNA encoding Transforming Growth Factor beta isoforms (TGF-β1, TGF-β2, and TGF-β3). This region contains various cis-acting elements, such as AU-rich elements (AREs) and microRNA (miRNA) binding sites, which control the stability and translation efficiency of the mRNA. In many pathological conditions, including advanced cancers and fibrotic diseases, TGF-β is overexpressed, leading to immunosuppression, epithelial-mesenchymal transition (EMT), and excessive extracellular matrix deposition. Therapeutic strategies targeting the TGF-β mRNA, including antisense oligonucleotides (ASOs) like Trabedersen and ISTH0036, aim to downregulate TGF-β production at the genetic level. These agents bind to the mRNA (often targeting regulatory regions like the 3'UTR or coding sequences) to induce degradation or block translation, thereby reversing the pro-tumorigenic and pro-fibrotic effects of the cytokine.
Antisense inhibition (RNase H-mediated degradation), Steric blocking of translation, Modulation of mRNA stability
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transforming growth factor beta messenger RNA 3' untranslated region (TGF-β mRNA 3'UTR).